Although secondary breast cancer causes virtually all 11,500 UK breast cancer deaths annually, The vast majority of UK breast cancer research funding is directed toward primary prevention, early detection, and cures for early-stage disease. It is estimated that only around 7% of breast cancer research funding in the UK and US is dedicated to metastatic disease.

Make 2nds Count tackles this through two vital solutions: • Dedicated Research: We commission studies focused purely on metastatic disease, tackling neglected priorities like brain metastases and symptom control to help patients live longer, better lives. • Clinical Trials Service: With 75% never offered a trial, our Patient Trial Advocates demystify complex criteria and match patients with innovative, life-extending studies, giving families more precious time together.